De traductores profesionales, empresas, páginas web y repositorios de traducción de libre uso.
‘sui’
“sui”
Última actualización: 2014-11-12
Frecuencia de uso: 2
Calidad:
model sui
mudell sui
Última actualización: 2014-11-12
Frecuencia de uso: 2
Calidad:
for sui, the recommended dose of ariclaim is 40 mg twice a day.
għal sui, id- doża rakkomandata ta 'ariclaim hija 40 mg darbtejn kuljum.
for sui, the recommended dose of duloxetine boehringer ingelheim is 40 mg twice a day.
għal sui, id- doża rakkomandata ta 'duloxetine boehringer ingelheim hija 40 mg darbtejn kuljum.
for the treatment of sui, ariclaim has been studied in a total of 2,850 women.
għat- trattament ta 'sui, ariclaim ġie studjat f' total ta' 2, 850 mara.
for the treatment of sui, duloxetine boehringer ingelheim has been studied in a total of 2,850 women.
għat- trattament ta 'sui, duloxetine boehringer ingelheim ġie studjat f' total ta' 2, 850 mara.
yentreve is used to treat moderate to severe stress urinary incontinence (sui) in women.
yentreve jintuża għat- trattament ta 'l- inkontinenza urinarja minn sforz (sui - stress urinary incontinence) minn moderata għal gravi fin- nisa.
sui is accidental leaks of urine during physical exertion or when coughing, laughing, sneezing, lifting or exercising.
sui sseħħ meta l-awrina tiskappa involontarjament matul l-isforz fiżiku jew wara li tisgħol, tidħaq, tagħtas, tgħolli oġġetti jew tagħmel eżerċizzji fiżiċi.
yentreve is a medicine to be taken by mouth to treat stress urinary incontinence (sui) in women.
yentreve huwa prodott mediċinali li jittieħed mill-ħalq għal kura ta’ inkontinenza awrinarja minħabba sforz (sui) fin-nisa.
for the purposes of this regulation, the term intellectual property rights means copyright, related rights, sui generis right for the protection of databases and industrial property rights.
għall-finijiet tar-regolament preżenti, l-espressjoni drittijiet ta’ proprjetà intellettwali tfisser id-dritt ta’ l-awtur, id-drittijiet anċillari, id-dritt sui generis għall-ħarsien tad-databases kif ukoll id-drittijiet ta’ proprjetà industrijali.
ariclaim is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui), (see section 5.1).
4. 1 indikazzjonijiet terapewtiċi